This open-label, single-arm, prospective cohort trial is the first phase 3 safety study to
describe outcomes in children treated with dabigatran etexilate for secondary venous …

Venous thromboembolism (VTE) incidence is increasing among children owing to many
factors, including improved diagnosis of VTE. There is a need for alternative treatment …

Essentials• Dabigatran etexilate may provide a new treatment option for pediatric venous
thromboembolism.• Children aged 1 to< 12 years were given dabigatran etexilate in an …

Background Dabigatran etexilate is a direct oral anticoagulant with potential to overcome the
limitations of standard of care in children with venous thromboembolism. The aims of this …

Background Dabigatran, which is administered in a fixed dose and does not require
laboratory monitoring, may be suitable for extended treatment of venous thromboembolism …

Objectives Age-related changes in the hemostatic system result in variation in response to
anticoagulants and coagulation assays over childhood. This study used in vitro methods to …

Common treatment options for deep vein thrombosis and venous thromboembolism in the
pediatric population include unfractionated heparin, low molecular weight heparin, and …

A number of novel anticoagulants are moving through various stages of drug development.
Recently, the United States Food and Drug Administration approved the oral direct thrombin …

OBJECTIVE: Dabigatran is a nov-el target specific oral anticoagulant for stroke prevention in
non valvular atrial fibrillation. Little is still known about its real-world effectiveness and safety …

Given the rising incidence of thrombotic complications in paediatric patients, understanding
of the pharmacologic behaviour of anticoagulant drugs in children has gained importance …